HiberCell News and Activities

HiberCell has a direct presence in 2 countries.

HiberCell has 7 subsidiaries including Genuity Science, STA Pharmaceutical and WuXi AppTec.

They are in:

• Biotechnology88%
• Pharmaceuticals13%

View the org chart displaying its 101 main executives

Most searched biographies at HiberCell

• Steven Gillis, Chairman and Acting Chief Executive Officer
• Cindy Jacobs, Director
• Jim Sullivan, Director

Create your alert
to follow the executive moves at HiberCell.

HiberCell has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by HiberCell

• HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 When Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting - HiberCell
• HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
• AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound - HiberCell
• HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC - HiberCell
• HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML) - HiberCell
• HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO - HiberCell
• Jonathan Lanfear Steps Down from Role as President and CEO. HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO. - HiberCell
• HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
• HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
• HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
• View more press releases Close

Social media about HiberCell

• HiberCell on Wikipedia, Google News & Yahoo Finance
• HiberCell on LinkedIn, X (Twitter) & YouTube